ClinicalTrials.gg
Active, not recruitingNCT07546812Updated Nov 10, 2026

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

A Phase 2 interventional study of Denikitug and Nivolumab in HER2-negative, Gastroesophageal Junction and Esophageal Adenocarcinoma, sponsored by Gilead Sciences. Active, not recruiting at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Now Active, not recruiting1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-15

Among 13 studies in Adenocarcinoma Of Esophagus with a site in Australia — 4 open to participants now, 6 under way, 3 of them phase 3. Adenocarcinoma Of Esophagus · Australia.

Planned enrollment
7th of 12
120 · median 400
Started
2026
with 2 others
Phase 2
2 of 13
none open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Gilead Sciences

Among the 13 studies in Adenocarcinoma Of Esophagus with a site in Australia, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 2, and was the 13th registered.

Adenocarcinoma Of Esophagus

354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 81 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

4 of the 13 studies in Adenocarcinoma Of Esophagus with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Adenocarcinoma Of Esophagus with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human epidermal growth factor receptor 2 (HER2)-Negative, unresectable, recurrent, and/or metastatic, gastroesophageal junction (GEJ), and esophageal adenocarcinomas.

The primary objective of this study is to assess the effect of DEN as a monotherapy or in combination with nivolumab (NIVO) or ramucirumab (RAM) and paclitaxel (PAC) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version1.1).

03

Conditions studied

  • HER2-negative
  • Gastroesophageal Junction
  • Esophageal Adenocarcinoma
  • Gastric Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed diagnosis of locally advanced, unresectable, or gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC).
  • Human epidermal growth factor receptor 2 ()-negative status, as determined by local assessment using a validated immunohistochemistry assay, in situ hybridization or other amplification testing.
  • Has had disease progression during or after of systemic therapy for advanced or metastatic gastric, GEJ, or EACs, which must have included at least one of the following:

    1. Platinum- and fluoropyrimidine-based chemotherapy.
    2. Therapy with an anti-programmed cell death protein 1 (PD1) or anti-programmed cell death ligand 1 () monoclonal antibody (patients with PD-L1-positive tumors must have received prior PD-1/PD-L1-based therapy).
    3. Zolbetuximab or other Claudin-18 (CLDN18).2-targeted therapy, if indicated based on biomarker status.
  • (ECOG) performance status score of 0-1.
  • Have adequate organ function.
  • Male individuals and female individuals of who engage in heterosexual intercourse must agree to use methods of .

Key Exclusion Criteria:

  • Active or history of disease requiring systemic treatment within 2 years, inflammatory bowel disease (IBD) (Crohn's/ulcerative colitis), celiac disease, or noninfectious enteritis/colitis. (Physiologic hormone replacement not considered systemic treatment).
  • History or current noninfectious pneumonitis/interstitial lung disease, including radiation-induced pneumonitis requiring or active/recurrent pneumonitis of any etiology.
  • Documented microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) disease by local polymerase chain reaction (PCR) (microsatellite status) and/or form (ICH) (mismatch repair (MMR)) assay
  • (For Part 2 only) Has known history of peripheral neuropathy ≥ Grade 2 (per National Cancer Institute(NCI)-Common Tenninology Criteria for Adverse Events () Version 5.0).
  • (For Part 2 only) Known coagulopathy that increases the risk of bleeding, bleeding diatheses. Any other Grade 3 or higher hemorrhage/bleeding event within 28 days prior to enrollment.

Prior/Concurrent Therapy or Clinical Study Experience

  • Prior treatment with DEN or other C-C chemokine receptor 8 (CCR8)-targeted agents.
  • Prior Lonsurf (trifluridine-tipiracil) or paclitaxel (PAC)-based regimens in the first-line setting for advanced/metastatic gastroesophageal adenocarcinoma.
  • Any systemic therapy (including ) targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) signaling pathways.
  • Anticancer biologic within 4 weeks, orchemotherapy, targeted small molecule, or radiation therapy within 2 weeks prior to enrollment with unresolved adverse events (AE)s (Grade >2). (Observational study participants are eligible).
  • Prior allogenic tissue/solid organ or stem cell transplantation. (Exception: corneal transplant not requiring systemic is allowed).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Part 1: Arm A: DEN (Dose A) and NIVO

    Participants will receive DEN Dose A as an IV infusion in combination with NIVO as an IV infusion.

    Drug: Denikitug · Drug: Nivolumab

  • Experimental
    Part 1: Arm B: DEN (Dose B) and NIVO

    Participants will receive DEN Dose B as an IV infusion in combination with NIVO as an IV infusion.

    Drug: Denikitug · Drug: Nivolumab

  • Experimental
    Part 1: Arm C: DEN (Dose B)

    Participants will receive DEN Dose B as an IV infusion.

    Drug: Denikitug

  • Experimental
    Part 2: Arm D: Safety Run-in (SRI) Cohort

    Participants will receive DEN in combination with ramucirumab (RAM) and paclitaxel (PAC). If dose for DEN is deemed safe during the SRI Cohort, the study will move forward into the Expansion Period.

    Drug: Denikitug · Drug: Ramucirumab · Drug: Paclitaxel

  • Experimental
    Part 2: Arm D: Expansion Cohort

    If DEN dose is deemed safe in Arm D: SRI Cohort, participants will receive DEN at recommended dose as an IV infusion in combination with RAM and PAC.

    Drug: Denikitug · Drug: Ramucirumab · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have achieved complete response (CR) or partial response (PR) as assessed by the investigator according to RECIST Version 1.1.

    Time frame: Up to 4 years

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the time of first response CR or PR as assessed by investigator, per RECIST Version 1.1 until the date of first documented progressive disease (PD) or death, whichever comes first.

    Time frame: Up to 4 years

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from date of first dose until PD or death from any cause, whichever comes first as assessed by the investigator according to RECIST Version 1.1.

    Time frame: Up to 4 years

  3. Overall Survival (OS)

    OS is defined as the length of time from first dose until the date of death from any cause.

    Time frame: Up to 4 years

  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: First dose date up to 120 days post last dose, up to 4 years.

  5. Percentage of Participants Experiencing Clinical Laboratory Abnormalities According to the NCI CTCAE v5.0

    Time frame: First dose date up to 120 days post last dose, up to 4 years.

  6. Pharmacokinetic (PK) Parameter: Serum concentration of DEN

    Time frame: Up to 4 years

  7. PK Parameter: Cmax for Denikitug

    Cmax is defined as the maximum observed concentration.

    Time frame: Up to 4 years

  8. PK Parameter: AUCall for Denikitug

    AUCall is defined as the cumulative areas under the curve for all time points.

    Time frame: Up to 4 years

  9. Percentage of Participants who Developed Treatment-Emergent Antidrug Antibody (ADA) Against Denikitug

    Time frame: Up to 4 years

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2030, 41 months after the start.

Of 60 phase 2 interventional studies under Adenocarcinoma Of Esophagus, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 80. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 23, 2026
StartActual
Aug 7, 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
1 site added
Show site
  • Hospital Universitario de Navarra · Pamplona, Spain
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    1 site added
    Show site
    • Hospital Universitario de Navarra · Pamplona, Spain
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07546812
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Aug 7, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Track this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to track

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denikitug

Start the discussion